More on NVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $148.12 |
|
|||
| Open | $152.00 | ||||
| 52 Wk High | $89.15 | ||||
| 52 Wk Low | $69.84 | ||||
| Day High | $152.58 | ||||
| Day Low | $151.62 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 985,851 | ||||
- Form 6-K NOVARTIS AG For: Jun 11
- Novartis reports positive biomarker results for experimental FSHD treatment
- Novartis to present Rhapsido data at allergy congress
- Novartis reports kidney function benefits for IgAN drug in phase III trial
- Novartis reports positive 144-week data for Scemblix in CML trial
- China holds roundtable with over 50 foreign pharmaceutical firms
- China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
- Novartis breaks ground on Texas radioligand therapy manufacturing site
- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
- Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G
Entities mentioned with NVS
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
